Navigation Links
Iomai to Announce Fourth Quarter and Year-End 2007 Financial Results and Host Webcast on Thursday, March 6
Date:3/3/2008

GAITHERSBURG, Md., March 3 /PRNewswire-FirstCall/ -- Iomai Corporation (Nasdaq: IOMI) today announced that it will release fourth quarter and year-end 2007 financial results before the markets open and hold a conference call and live webcast to discuss corporate and clinical progress on Thursday, March 6, 2008 at 1:30 p.m. Eastern Time.

Conference Call Details

To access the live conference call on Thursday, March 6 at 1:30 p.m. Eastern Time via phone, please dial 866-578-5784 from the United States and Canada or +1-617-213-8056 internationally. The conference ID is 87233725. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through March 10 and may be accessed by dialing 888-286-8010 from the United States and Canada or +1-617-801-6888 internationally. The replay passcode is 74369365.

To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the Company's website at http://www.iomai.com. Please connect to the web site at least 15 minutes prior to the call to allow for any software download that may be necessary. The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at http://www.earnings.com, Thomson's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (http://www.streetevents.com), a password-protected event management site.

About Iomai Corporation

Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: three targeting influenza and pandemic flu and one to prevent travelers' diarrhea. For more information on Iomai, please visit http://www.iomai.com.


'/>"/>
SOURCE Iomai Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Iomai CEO to Speak at BIO CEO & Investor Forum on Feb. 12
2. Iomai to Announce Third Quarter 2007 Financial Results and Host Webcast on Tuesday, November 13
3. Iomai Chief Scientific Officer Dr. Gregory Glenn Details Development of Travelers Diarrhea Patch at Keystone Conference
4. Iomai CEO to Speak at Natixis Bleichroeder Hidden Gems Conference on Monday
5. Rosetta Genomics Announces Allowance of Two Additional microRNA Patents
6. ROBODOC(R) Announces Patent Cross Licensing Agreement With IBM
7. MiMedx Announces Brian J. Splan as President
8. Boston Scientific Announces European Approval of New Heart Failure Lead
9. WaferGen Announces Management Team Promotions
10. Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3)
11. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... for Amgen, will join the faculty of the University of North Carolina ... professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the ...
(Date:6/27/2016)... June 27, 2016   Ginkgo Bioworks , a ... engineering, was today awarded as one of the ... the world,s most innovative companies. Ginkgo Bioworks is ... the real world in the nutrition, health and ... directly with customers including Fortune 500 companies to ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016   Acuant ... and verification solutions, has partnered with RightCrowd ... solutions for Visitor Management, Self-Service Kiosks and ... products that add functional enhancements to existing ... corporations and venues with an automated ID ...
(Date:6/15/2016)... June 15, 2016 Transparency ... titled "Gesture Recognition Market by Application Market - Global Industry Analysis ... 2024". According to the report, the  global gesture recognition ... 2015 and is estimated to grow at a ... by 2024.  Increasing application of gesture ...
(Date:6/2/2016)... , June 2, 2016 The ... has awarded the 44 million US Dollar project, for ... Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... leader in the production and implementation of Identity Management Solutions. ... January, however Decatur was selected for ...
Breaking Biology News(10 mins):